NIH Plans December Cancer Vaccine Partnership Targeting 4 Tumor Types
Updated
Updated · The New York Times · Oct 9
NIH Plans December Cancer Vaccine Partnership Targeting 4 Tumor Types
2 articles · Updated · The New York Times · Oct 9
Summary
December is the planned launch for an NIH-led public-private partnership to develop and test personalized cancer vaccines, beginning with pancreatic, liver and colorectal cancers plus a subset of pediatric tumors.
The National Cancer Institute says the vaccines are promising enough to warrant a national push because they train T cells to attack aberrant proteins unique to each patient's tumor.
The effort will bring together NIH, the Foundation for the NIH, researchers, drugmakers, biotech companies, advocacy groups, philanthropies and patients to speed work that officials say would not otherwise happen.
Officials said they hope to replicate the Covid-vaccine model, using a broad public-private collaboration to accelerate discovery and clinical testing in a new cancer treatment field.